Food/Recall·FDA Recalls, Market Withdrawals & Safety Alerts

NARA ORGANICS RECALLS ALL LOTS OF NARA INFANT FORMULA BECAUSE OF POSSIBLE HEALTH RISK

CriticalPublished Jun 13, 2026· AI-analyzed Jun 14, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Nara Organics is voluntarily recalling all lots of Nara Organics Powdered Infant Formula due to potential contamination with Clostridium botulinum.

Who it affects

This recall affects Nara Organics, infant formula distributors, retailers, and healthcare professionals managing infant nutrition.

Why it matters

The potential presence of Clostridium botulinum in infant formula represents an acute safety risk, as infant botulism can be fatal. This comprehensive recall suggests a significant breakdown in sterility assurance or raw material sourcing. For regulatory professionals, this underscores the high level of scrutiny applied to the infant formula category and the necessity for immediate, transparent corrective actions when a pathogen risk is identified.

Practical takeaway

Immediately identify and quarantine all lots of Nara Organics Powdered Infant Formula within the supply chain. QA teams should verify that all distribution partners are notified and that reconciliation of recalled units is documented for FDA inspection. Update safety monitoring protocols to prioritize any reports of infant illness potentially linked to these products.

FDA source material

Nara Organics of New York, NY, is voluntarily recalling all lots of Nara Organics Powdered Infant Formula currently on the market out of an abundance of caution due to the potential risk of Clostridium botulinum contamination.<br> Infant botulism is a rare but potentially fatal illness that presents a s

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.